Hear leading clinicians and researchers offer their perspectives on how data and trial results presented at the American Diabetes Association 2010 annual meeting will impact clinical practice now and in the future.

The objective of the activities is address outstanding questions related to the impact of growth hormone therapy on final height and quality of life in patients with idiopathic short stature based on new data from randomized clinical trials, and for learners to utilize this data to apply changes into their clinical practice and improve patient outcomes.

Hyperinsulinemic hypoglycemia is the most dangerous form of hypoglycemia. It can lead to irreversible brain damage if not accurately diagnosed. Tremendous progress has been made in this field over the past 10 to 15 years and it is imperative that health care professionals who encounter these patients are knowledgeable of the most up-to-date methods of diagnosis and treatment. This monograph will review the history of hyperinsulinism along with its pathophysiology, potential etiologies, and clinical features. Current methods for diagnosis and treatment of hyperinsulinism will be reviewed.

Management of patients with growth disorders is becoming increasingly complex, with a range of medications that may affect a patient’s growth and expanding uses of growth hormone treatment. Pediatric endocrine physicians and nurses must also be able to counsel patients who are not candidates for treatment. This monograph will review medications that have an impact on growth, as well as the conditions for which growth hormone therapy is indicated. Importantly, strategies for working with families with normal variant short stature, for which growth hormone therapy is not indicated, will be discussed.